Y-Biologics, Inc. (KOSDAQ:338840)

Y-Biologics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	2,509	38,922	9,083	20,535	12,614	16,873
Short-Term Investments	35,207	3,031	3,000	362.11	368.9	74.96
Trading Asset Securities	775.05	2,316	120.49	-	-	-
Cash & Short-Term Investments	38,492	44,269	12,204	20,898	12,983	16,948
Cash Growth	298.71%	262.75%	-41.60%	60.97%	-23.40%	-49.24%
Accounts Receivable	121.02	25.96	63.87	573.37	689.88	825.19
Other Receivables	13.45	238.41	27.78	21.97	0.67	317.93
Receivables	134.47	264.37	91.64	595.34	690.55	1,143
Prepaid Expenses	108.74	50.44	42.91	89.29	20.2	91.4
Other Current Assets	958.79	231.05	132.56	180.33	845.17	1,663
Total Current Assets	39,694	44,815	12,471	21,763	14,538	19,845
Property, Plant & Equipment	7,230	6,899	7,407	8,009	10,801	16,824
Long-Term Investments	642.89	2,049	89.03	-	-	-
Other Intangible Assets	503.9	530.88	223.37	247.18	316.56	279.35
Other Long-Term Assets	2,121	1,504	1,538	275.5	3,667	1,296
Total Assets	50,192	55,798	21,727	30,294	29,323	38,245

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	12.62	0.27	3.23	1.21	-	-
Accrued Expenses	193.11	214.41	243.31	205.33	224.38	352.99
Short-Term Debt	40	65	-	2,000	-	-
Current Portion of Long-Term Debt	-	-	500	-	4,528	2,336
Current Portion of Leases	175.01	181	153.57	192.47	223.39	516.5
Other Current Liabilities	1,246	778.63	262	508.83	3,569	3,003
Total Current Liabilities	1,667	1,239	1,162	2,908	8,545	6,209
Long-Term Debt	16,096	14,366	-	500	-	2,528
Long-Term Leases	159.8	141.13	125.19	200.01	188.1	574.62
Other Long-Term Liabilities	15,070	13,454	802.45	677.72	645.96	491.76
Total Liabilities	32,993	29,200	2,090	4,286	9,379	9,803

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	7,683	7,589	7,391	7,381	6,145	6,141
Additional Paid-In Capital	179,978	176,041	124,295	122,727	93,385	93,287
Retained Earnings	-174,459	-162,315	-120,290	-113,849	-92,978	-74,173
Comprehensive Income & Other	3,997	5,283	6,960	7,149	5,741	3,186
Total Common Equity	17,198	26,597	18,356	23,408	12,293	28,441
Shareholders' Equity	17,198	26,597	19,637	26,008	19,943	28,441
Total Liabilities & Equity	50,192	55,798	21,727	30,294	29,323	38,245

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	16,471	14,753	778.76	2,892	4,940	5,955
Net Cash (Debt)	22,020	29,516	11,425	18,005	8,043	10,992
Net Cash Growth	145.87%	158.35%	-36.55%	123.86%	-26.83%	-60.80%
Net Cash Per Share	1456.08	1981.91	773.28	1438.09	654.40	903.42
Filing Date Shares Outstanding	15.35	15.18	14.78	14.76	12.29	12.17
Total Common Shares Outstanding	15.35	15.18	14.78	14.76	12.29	12.17
Working Capital	38,027	43,575	11,309	18,855	5,993	13,636
Book Value Per Share	1120.67	1752.35	1241.72	1585.65	1000.22	2337.50
Tangible Book Value	16,694	26,066	18,132	23,161	11,977	28,162
Tangible Book Value Per Share	1087.84	1717.38	1226.61	1568.90	974.46	2314.54
Land	749.16	749.16	749.16	594.79	594.79	594.79
Buildings	4,326	4,326	4,326	3,370	3,370	3,370
Machinery	11,846	10,781	10,580	10,479	12,144	11,635
Construction In Progress	356.24	340.51	317.23	377.82	301.48	3,703

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 8, 2026

Data Sources Report a data error